GlassScriptPhysician profile
Alfred D Belen
NPI 1386776847
$7,764.67
in general payments reported to CMS, 2019-2025
31 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $1,161 · 2021: $1,046 · 2022: $977 · 2023: $1,287 · 2024: $899 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.05 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,434.61 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $918.68 | 2019-2025 | Rexulti |
| Abbvie INC. | $739.09 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $726.86 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $628.25 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $620.52 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $531.71 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $370.35 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $268.01 | 2023-2024 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $215.51 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $177.26 | 2022-2024 | Quviviq |
| Allergan, INC. | $140.23 | 2020 | |
| Alkermes, INC. | $116.02 | 2019-2025 | Aristada, Lybalvi |
| Livanova USA, INC. | $115.37 | 2022-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Sage Therapeutics, LLC | $111.37 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $99.94 | 2019-2021 | |
| Neos Therapeutics, LP | $84.58 | 2025 | Exxua |
| Vifor Pharma, INC. | $66.31 | 2019-2020 | |
| Biogen, INC. | $54.13 | 2022-2023 | |
| Amgen INC. | $46.83 | 2019-2021 | |
| Neuronetics, INC. | $43.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.01 | 2019-2020 | |
| Bausch Health US, LLC | $41.56 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.51 | 2019 | |
| Sunovion Pharmaceuticals INC. | $34.01 | 2021 | |
| Medtronic, INC. | $23.56 | 2024 | Venaseal |
| Owp Pharmaceuticals, INC. | $21.46 | 2025 | Subvenite |
| Aurinia Pharma U.S., INC. | $19.96 | 2021 | |
| Fresenius USA Marketing, INC. | $19.67 | 2021 | |
| Eisai INC. | $12.18 | 2021 | |
| Ge Healthcare | $3.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Belen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.